Adenocarcinoma - Pipeline Review, H2 2012

Description: Adenocarcinoma – Pipeline Review, H2 2012

Summary

Global Markets Direct's, 'Adenocarcinoma - Pipeline Review, H2 2012', provides an overview of the Adenocarcinoma therapeutic pipeline. This report provides information on the therapeutic development for Adenocarcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Adenocarcinoma. 'Adenocarcinoma - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Adenocarcinoma.
- A review of the Adenocarcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Adenocarcinoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Adenocarcinoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Adenocarcinoma pipeline depth and focus of Adenocarcinoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Adenocarcinoma Therapeutic Products under Development, Key Players in Adenocarcinoma Therapeutics, Adenocarcinoma Pipeline Overview, Adenocarcinoma Pipeline, Adenocarcinoma Pipeline Assessment

Contents:

2 List of Tables
6 List of Figures
8 Introduction

REPORT COVERAGE 8
Erlotinib - Drug Profile 192
S1+ Leucovorin + Oxaliplatin + Gemcitabine - Drug Profile 193
Xeloda + Taxotere - Drug Profile 195
5-Fluorouracil + Epirubicin + Cisplatin + Radiation Therapy - Drug Profile 197
5-Fluorouracil + Epirubicin + Irinotecan + Radiation Therapy - Drug Profile 199
GS-6624 + FOLFIRI - Drug Profile 201
AMG 172 - Drug Profile 203
Carboplatin + Paclitaxel + RAD001 - Drug Profile 204
5-Fluorouracil + Leucovorin + Docetaxel + Oxaliplatin + Trastuzumab - Drug Profile 205
Oxaliplatin + S-1 - Drug Profile 207
PEI/DNA + Gemzar - Drug Profile 208
BKM120 + LDE225 - Drug Profile 210
Adenocarcinoma Therapeutics – Drug Profile Updates 211
Adenocarcinoma Therapeutics – Discontinued Products 221
Adenocarcinoma Therapeutics - Dormant Products 223
Adenocarcinoma – Product Development Milestones 229
Featured News & Press Releases 229
Appendix 231
Methodology 231
Coverage 231
Secondary Research 231
Primary Research 231
Expert Panel Validation 231
Contact Us 232
Disclaimer 232

List of Tables
Number of Products Under Development for Adenocarcinoma, H2 2012 16
Products under Development for Adenocarcinoma – Comparative Analysis, H2 2012 17
Number of Products under Development by Companies, H2 2012 19
Number of Products under Development by Companies, H2 2012 (Contd..1) 20
Number of Products under Investigation by Universities/Institutes, H2 2012 22
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 23
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 24
Comparative Analysis by Late Stage Development, H2 2012 25
Comparative Analysis by Mid Clinical Stage Development, H2 2012 26
Comparative Analysis by Early Clinical Stage Development, H2 2012 27
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 28
Products under Development by Companies, H2 2012 29
Products under Development by Companies, H2 2012 (Contd..1) 30
Products under Investigation by Universities/Institutes, H2 2012 31
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 32
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 33
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 34
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 35
F. Hoffmann-La Roche Ltd., H2 2012 36
Amgen Inc., H2 2012 37
Sanofi-Aventis, H2 2012 38
Eli Lilly and Company, H2 2012 39
Gilead Sciences, Inc., H2 2012 40
BioLineRx, Ltd., H2 2012 41
Novartis AG, H2 2012 42
Astellas Pharma Inc., H2 2012 43
Pfizer Inc., H2 2012 44
Aduro BioTech, H2 2012 45
Celgene Corporation, H2 2012 46
Merck KGaA, H2 2012 47
Novartis Pharmaceuticals Corporation, H2 2012 48
Alchemia Limited, H2 2012 49
Cellldex Therapeutics, Inc., H2 2012 50
Lorus Therapeutics Inc, H2 2012 51
AVAX Technologies, Inc., H2 2012 52
Oncolytics Biotech Inc., H2 2012 53
Threshold Pharmaceuticals, Inc., H2 2012 54
GANYMED Pharmaceuticals AG, H2 2012 55
Merrimack Pharmaceuticals, Inc., H2 2012 56
Axcentua Pharmaceuticals AB, H2 2012 57
BioCancell Therapeutics, Inc., H2 2012 58
Kinex Pharmaceuticals, LLC, H2 2012 59
Assessment by Monotherapy Products, H2 2012 60
Assessment by Combination Products, H2 2012 61
Assessment by Stage and Route of Administration, H2 2012 64
Assessment by Stage and Molecule Type, H2 2012 67
Adenocarcinoma Therapeutics – Drug Profile Updates 217
Adenocarcinoma Therapeutics – Discontinued Products 227
Adenocarcinoma Therapeutics – Discontinued Products (Contd..1) 228
Adenocarcinoma Therapeutics – Dormant Products 229
Adenocarcinoma Therapeutics – Dormant Products (Contd..1) 230
Adenocarcinoma Therapeutics – Dormant Products (Contd..2) 231
Adenocarcinoma Therapeutics – Dormant Products (Contd..3) 232
Adenocarcinoma Therapeutics – Dormant Products (Contd..4) 233
Adenocarcinoma Therapeutics – Dormant Products (Contd..5) 234

List of Figures
Number of Products under Development for Adenocarcinoma, H2 2012 16
Products under Development for Adenocarcinoma – Comparative Analysis, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 21
Late Stage Products, H2 2012 25
Mid Clinical Stage Products, H2 2012 26
Early Clinical Stage Products, H2 2012 27
Discovery and Pre-Clinical Stage Products, H2 2012 28
Assessment by Monotherapy Products, H2 2012 60
Assessment by Combination Products, H2 2012 61
Assessment by Route of Administration, H2 2012 62
Assessment by Stage and Route of Administration, H2 2012 63
Assessment by Molecule Type, H2 2012 65
Assessment by Stage and Molecule Type, H2 2012 66

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/2233967/]
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Adenocarcinoma - Pipeline Review, H2 2012
Web Address: http://www.researchandmarkets.com/reports/2233967/
Office Code: SCD2I6ZZ

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________________________ Last Name: ___________________________________________
Email Address: * _______________________________________
Job Title: _____________________________________________
Organisation: __________________________________________
Address: _____________________________________________
City: _________________________________________________
Postal / Zip Code: ____________________________________
Country: _____________________________________________
Phone Number: _________________________________________
Fax Number: __________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp